Novocure LTD 10-Q quarterly reports

NovoCure Limited reported a 16% increase in net revenues for Q2 2026, driven by patient growth and new product contributions, while managing operating expenses and investing in future development.

NovoCure Limited announced its first-quarter 2026 financial results, reporting a 12% increase in net revenues to $174.1 million, driven by international market growth, while net loss widened due to increased operating expenses.

NovoCure Limited reported an 8% increase in net revenues for Q3 2025, reaching $167.2 million, but saw net losses widen to $37.3 million and Adjusted EBITDA turn negative.

NovoCure Limited announced its second quarter 2025 financial results, showing a 6% increase in net revenues to $158.8 million, driven by patient growth and international market expansion, despite a widening net loss and reduced gross margin.

NovoCure Limited reports a 12% increase in net revenues for Q1 2025, driven by active patient growth and reimbursement improvements.

NovoCure's Q3 2024 results show a 22% increase in net revenue year-over-year, driven by growth in the US and a successful launch in France.

NovoCure's Q2 2024 results show a 19% increase in revenue year-over-year, driven by international market expansion and improved U.S. approval rates, despite a net loss.

NovoCure Limited's first quarter 2024 results show a 13% increase in net revenues, reaching $138.5 million, driven by growth in international markets and improved U.S. approval rates.